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Abstract 
The fourth “Melanoma Bridge Meeting” took place in Naples, December 3–6th, 2014. The four topics discussed at 
this meeting were: Molecular and Immunological Advances, Combination Therapies, News in Immunotherapy, and 
Tumor Microenvironment and Biomarkers. Until recently systemic therapy for metastatic melanoma patients was 
ineffective, but recent advances in tumor biology and immunology have led to the development of new targeted 
and immunotherapeutic agents that prolong progression-free survival (PFS) and overall survival (OS). New therapies, 
such as mitogen-activated protein kinase (MAPK) pathway inhibitors as well as other signaling pathway inhibitors, are 
being tested in patients with metastatic melanoma either as monotherapy or in combination, and all have yielded 
promising results. These include inhibitors of receptor tyrosine kinases (BRAF, MEK, and VEGFR), the phosphatidylino-
sitol 3 kinase (PI3K) pathway [PI3K, AKT, mammalian target of rapamycin (mTOR)], activators of apoptotic pathway, 
and the cell cycle inhibitors (CDK4/6). Various locoregional interventions including radiotherapy and surgery are still 
valid approaches in treatment of advanced melanoma that can be integrated with novel therapies. Intrinsic, adaptive 
and acquired resistance occur with targeted therapy such as BRAF inhibitors, where most responses are short-lived. 
Given that the reactivation of the MAPK pathway through several distinct mechanisms is responsible for the major-
ity of acquired resistance, it is logical to combine BRAF inhibitors with inhibitors of targets downstream in the MAPK 
pathway. For example, combination of BRAF/MEK inhibitors (e.g., dabrafenib/trametinib) have been demonstrated 
to improve survival compared to monotherapy. Application of novel technologies such sequencing have proven 
useful as a tool for identification of MAPK pathway-alternative resistance mechanism and designing other combina-
torial therapies such as those between BRAF and AKT inhibitors. Improved survival rates have also been observed 
with immune-targeted therapy for patients with metastatic melanoma. Immune-modulating antibodies came to the 
forefront with anti-CTLA-4, programmed cell death-1 (PD-1) and PD-1 ligand 1 (PD-L1) pathway blocking antibodies 
that result in durable responses in a subset of melanoma patients. Agents targeting other immune inhibitory (e.g., 
Tim-3) or immune stimulating (e.g., CD137) receptors and other approaches such as adoptive cell transfer demon-
strate clinical benefit in patients with melanoma as well. These agents are being studied in combination with targeted 
therapies in attempt to produce longer-term responses than those more typically seen with targeted therapy. Other 
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Background
Opening ceremony included the lecture of Giorgio Par-
miani, MD who was the 2014 awardee from the FON-
DAZIONE MELANOMA ONLUS that is one of the 
sponsors of the meeting. Awards are presented each year 
for outstanding scientific achievements in the field of 
melanoma.
The Fondazione awarded Giorgio Parmiani in recogni-
tion of his outstanding research and achievements in can-
cer therapy. Giorgio Parmiani holds an MD degree from 
the University of Milan and he is currently the Head of 
the Unit of Immuno-Biotherapy of Melanoma and Solid 
Tumors at the San Raffaele Foundation Scientific Insti-
tute. Dr. Parmiani’s research interests have been focused 
on the study of molecular characterization of human 
tumor Antigens and the T cell response, particularly in 
melanoma patients. His interests have also focused on 
studies of immunotherapy in melanoma, colorectal, and 
prostate cancer patients, primarily with gene-modified 
cellular vaccines, along with peptides or heat-shock pro-
tein-based vaccines. Dr. Parmiani presented the Award 
lecture during the Opening Ceremony.
Giorgio Parmiani award lecture
Anti-tumor immune response have to be considered as a 
dynamic system, where the activation of B and T lympho-
cytes (helper CD4+ and cytotoxic CD8+, respectively) is 
counterbalanced by the suppression from T-regulatory 
(Treg), dysfunctional myeloid cells (myeloid-derived sup-
pressor cells, MDSC); immature dendritic cells (iDC) and 
T and B “exhausted” or anergic lymphocytes. In primary 
melanoma, the density and distribution of tumor-infil-
trating lymphocytes (TILs) is a positive and independent 
prognostic factor. Patients with grade 3 TILs infiltra-
tion, defined as dense and diffuse lymphocytes infiltrate 
throughout the tumor have better survival as compared 
with those without infiltration [1]. These findings indi-
cated the potential of the therapeutic use of vaccines in 
metastatic melanoma (MM) patients. Both normal sub-
jects and melanoma patients show tolerance to “self” 
melanoma-associated antigens (MAAs). Tolerance needs 
to be broken in order to induce a T-cell immune response 
against “self” MAAs which are considered to be “weak” 
antigens.
Most common MAAs recognized by T-cells includ-
ing melanoma differentiation antigens (e.g. MART-
1, GP100), cancer testis antigens (e.g., MAGE-1, 
NY-ESO-1), mutated antigens (neo-antigens) and 
oncogenic transformation-associated antigens includ-
ing oncogenes (BRAF, survivin, telomerase) are overex-
pressed in melanoma. Early stages of melanoma vaccines 
development (1995–2008) have been based on whole 
cell and peptide-specific antigens such as MAGE-3 and 
Melan-A/MART-1. Clinical trials results of first genera-
tion self-peptide-based vaccination in MM patients were 
dismal (1998–2008). Phase I–II trials with vaccines in 
MM patients showed less than 20 % of objective response 
rate (ORR) but 20–65 % of immune response rate (IRR) 
[2]. Dendritic cells (DC) presented antigens have been 
demonstrated to be superior to peptides as MAGE-3.
A1-based vaccine. Nonetheless, only few patients experi-
enced an immune response as well as partial or complete 
clinical responses to vaccine therapy [3]. However, posi-
tive overall response (OS) in a phase 3 study have been 
reached with GP100 [4] and dendritic cells-based vac-
cines [5] although such responses were delayed and were 
often long lasting.
In the following years, due to the scientific advances 
in immunology and tumor biology, clinical trials gener-
ated more promising results for treatment of melanoma 
patients with vaccines [4–7]. New generation vaccines, 
developed using different strategies, showed more prom-
ising results in patients with solid tumors, including MM. 
A systematic review of new generation vaccines, includ-
ing 4375 patients from 56 clinical trials in MM, showed 
an overall disease control rate (DCR) in 25 % of patients 
[8]. The presence of a tumor-specific immune response 
was associated with prolonged overall survival but there 
was no evidence that anti-melanoma vaccines provide 
better OS as compared to other treatments.
combinations with cytotoxic chemotherapy and inhibitors of angiogenesis are changing the evolving landscape 
of therapeutic options and are being evaluated to prevent or delay resistance and to further improve survival rates 
for this patient population. This meeting’s specific focus was on advances in combination of targeted therapy and 
immunotherapy. Both combination targeted therapy approaches and different immunotherapies were discussed. 
Similarly to the previous meetings, the importance of biomarkers for clinical application as markers for diagnosis, 
prognosis and prediction of treatment response was an integral part of the meeting. The overall emphasis on bio-
markers supports novel concepts toward integrating biomarkers into contemporary clinical management of patients 
with melanoma across the entire spectrum of disease stage. Translation of the knowledge gained from the biology of 
tumor microenvironment across different tumors represents a bridge to impact on prognosis and response to therapy 
in melanoma.
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The lack of predictive factors for efficacy that will allow 
to select patients for treatment is a critical factor and a 
challenge for melanoma immunotherapy. In an adju-
vant phase III trial (DERMA trial) which enrolled 1349 
radically resected, stage IIIB–IIIC melanoma patients, 
MAGE-A3 vaccine did not reach its primary endpoint 
of disease-free survival (DFS) prolongation as compared 
with observation but a gene signature was developed 
with a potential to predict a response to the vaccine [9].
Other important options in the development of mela-
noma vaccines are the combination with chemotherapy 
and with molecularly targeted treatment agents (e.g., 
vemurafenib) that can also modulate the immune system. 
New immunotherapeutic approaches such as immuno-
checkpoint inhibitors (anti-CTLA4, anti-PD-1, and anti-
PD-L1) that already have changed the strategies of MM 
treatment due to their therapeutic efficacy should also be 
considered. Accumulation of immunosuppressive cells 
in the blood [such as MDSC cells and Treg is associated 
with advanced disease stage in melanoma and in prostate 
cancer patients [10]. One of the most effective immune-
stimulatory mechanisms would be down-regulation of 
both Treg cells and MDSC, which can result from vac-
cination against MAAs. Preliminary results showed that 
a treatment with ipilimumab could help triggering a clini-
cally effective MAA-specific response on patients with 
MM targeting self/shared and/or mutated antigens.
Given the recent progress regarding genome sequenc-
ing technologies, the possibility of identifying new 
somatic mutation in genes encoding tumor-specific 
antigens for individual patient allow to build personal-
ized melanoma vaccines. Immune responses to peptide 
sequences derived from neo-antigens was observed in 
melanoma patients who demonstrated a response to 
CTLA-4 blockade [11]. These findings provide a ration-
ale for exome sequencing to identify mutational load as 
predcictive marker of response for patients for whom 
checkpoint blockade therapy is considered,
Combination therapies
Targeted therapy combinations
Melanoma is a genetically heterogeneous disease, with 
oncogenic driver mutations which are present in most 
tumors. The Cancer Genome Atlas Research (TCGA) 
Network established four subtypes of cutaneous mela-
noma based on mutation in BRAF, RAS, NF1 genes 
and Triple Wild-Type. Tumors driven by V600-BRAF 
mutations that are highly sensitive to RAF-inhibitors. 
RAS  and  NF1  mutant melanomas have deregulated 
MEK signaling may be responsive to MEK inhibitors. 
RAS,  NF1, and Triple Wild-Type cancers all demon-
strated overexpression of  AKT3, a protein kinase that 
affects MEK and mTOR signaling pathways, suggesting 
that MEK and PI3K/AKT/mTOR pathway inhibitors 
could target this molecular alteration. Patients with met-
astatic melanoma with greater numbers of immune cells 
infiltrating tumors in the lymph nodes and enhanced 
T-cell signaling experienced better outcomes.
The plasticity of human tumor cells generally replicates 
normal molecular processes occurring during develop-
ment and tissue repair. In humans, cancer progression 
is also shaped by host immune responses that edit the 
final tumor-host interactions. The genetic complexity and 
extreme variability of human melanoma means a mul-
tidisciplinary integrative approach is needed to under-
stand the interactions between the genetic background of 
the host, the tumor and its microenvironment, and the 
impact of these on the immune system [12]. It is evident 
that successful anti-tumor strategies need to encompass 
a multimodal approach to avoid tumor escape or relapse, 
combining agents able to block essential signal transduc-
tion pathways with immunotherapy [12].
Earlier studies have identified specific mechanisms 
of BRAF inhibitor resistance in melanoma, which may 
reflect different temporal processes (early adaptive and 
late acquired resistance) [13, 14]. An example of the 
adaptive response is the upregulation of receptor tyros-
ine kinases with correlated AKT activation. Heterogene-
ous mechanisms of acquired BRAF inhibitor resistance 
in melanoma support the notion of MAPK and PI3K-
AKT as two core resistance pathways. Key mechanisms 
include emergence of mutant BRAF-concurrent RAS 
or MEK mutations and mutant BRAF amplification or 
alternative splicing, but the relative contribution of non-
genetic mechanisms to clinical disease progression is 
unknown. Distinct molecular lesions, in both core drug 
escape pathways, were commonly detected concurrently 
in the same tumor or among multiple tumors from the 
same patient. Beyond harboring extensively heterogene-
ous resistance mechanisms, melanoma re-growth emerg-
ing from BRAF inhibitor selection displayed branched 
evolution marked by altered mutational spectra/signa-
tures and increased fitness. Thus, melanoma genomic 
heterogeneity contributes significantly to BRAF inhibi-
tor treatment failure; co-targeting of two core pathways 
is an essential strategy for durable responses. Moreover, 
a clinical strategy to mitigate acquired BRAF inhibi-
tor resistance by combined BRAF and MEK inhibition, 
although prolonging tumor suppression, is still beset by 
acquired drug resistance, suggesting MAPK-alternate 
escape routes. However, a genomic analysis of acquired 
double-drug resistance revealed a plethora of genetic 
alterations responsible for acquired single-drug (i.e., 
BRAF inhibitor) resistance. Further analysis uncovered 
that these genetic mechanisms often occurred in configu-
rations indicating concurrent or exaggerated gene dosage 
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alterations. A hallmark of acquired double-drug resist-
ance in melanoma is augmentation of mutant BRAF gene 
dosage, e.g., V600E-BRAF ultra-amplification, mutant 
NRAS amplification, and homozygous loss of CDKN2A 
or PTEN. Examples of concurrent genetic alterations 
detected included: V600E-BRAF amplification + mutant 
MEK, V600E-BRAF amplification  +  DUSP4 loss and 
mutant NRAS + loss of PTEN. These genomic alteration 
patterns can result in profound alterations in the mode 
of signaling. For instance, in mediating MAPK pathway 
reactivation, up-expressed V600E BRAF dimerizes and 
activates CRAF or forms a complex with mutated BRAF; 
specific protein–protein interfaces were identified in 
these escape modes of MAPK pathway activation. Thus, 
even with the clinical superiority of combined BRAF/
MEK inhibitors, melanoma nevertheless displays MAPK 
pathway addiction in acquiring resistance, suggesting 
that additional strategies to target the MAPK pathway are 
needed. Also, genomic analysis of acquired double-drug 
resistance does not readily identify accountable mecha-
nisms in a large segment of clinical cases, suggesting a 
prevalence of non-genomic mechanisms. Lastly, acquired 
double-drug resistant melanoma clones were found to 
be highly addicted to the inhibitors, suggesting that drug 
addiction may be clinically viable strategy, through inter-
mittent dosing, to suppress acquired resistance.
Inhibiting multiple pathways such as BRAF (vemu-
rafenib or dabrafenib) and MEK (trametinib and cobem-
etinib) is a very promising and valuable approach in 
patients with MM. Combination BRAF/MEK inhibition 
could offer some advantages, despite of a median PFS 
of less than 10  months in one study. Double blocking 
strategy may be better than expected, producing tumor 
response in the majority of patients and sometimes dura-
ble CRs. Dabrafenib/trametinib combination therapy 
showed a prolonged OS benefit and greater response 
rate in patients with M1a/M1b disease and normal 
LDH values [15]. Both in the COMBI-V and COMBI-
D randomized trials OS was significantly greater in the 
dabrafenib plus trametinib arm as compared with the 
vemurafenib or dabrafenib-only arm, with at least 30 % of 
death reduction rate favoring the combination arm [15–
17]. Similar results have been reached in CoBRIM rand-
omized trial [18].
Patients treated in the BRIM2 phase II study of vemu-
rafenib in previously treated patients with BRAFV600E 
mutation and those treated with MEK-inhibitor cobi-
metinib  +  vemurafenib in the BRIM7 study have been 
evaluated for correlation between activity and intensity 
of MAP-Kinase inhibition [19]. When compared indi-
rectly across the two studies, the combination of cobi-
metinib +  vemurafenib resulted in enhanced inhibition 
of ERK phosphorylation and enhanced downregulation 
of transcriptional targets downstream of ERK at cycle 1 
day 14 compared to vemurafenib monotherapy. The com-
bination also inhibits pS6 signaling (82 %) and phosporyl-
ation of other mTORC-regulated proteins such as 4EBP1, 
eIF2a and eIF4G in BRAF-i naive patients. Targeting 
signaling initiated by NRAS and CDK4 are generating 
considerable interest and may lead to arrest of G1-S cycle 
cell progression or induction of senescence. Very promis-
ing drugs such as palbociclib a CDK4-inhibitor are being 
investigated preclinically and clinical investigation has 
commenced. In order to develop a new platform for drug 
development in MM the Melanoma International Collab-
oration for Adaptive Trials (MICAT) has been created. 
The goals of this study are to identify the most active 
combinations in advanced melanoma, identify the inter-
action with established and emerging biomarkers with 
the novel therapies, and to address key questions about 
sequencing strategy. BRAF regulates a complex network 
of transcription factors controlling glycolysis, involv-
ing MYC, MONDO-A and HIF1-alfa as final steps [20]. 
Rapid metabolic response is a typical feature following 
inhibition of BRAF and novel combinations are welcome 
to further enhance disease shrinkage. Another promis-
ing approach in mutated patients was the combination 
of BRAF-inhibitor with a PI3K inhibitor, which showed 
synergic activity in  vitro [21]. Preliminary data of the 
combination of vemurafenib plus PX-866 showed dura-
ble ongoing responses in both treatment-naive and prior 
BRAFi or MEKi treated patients NCT01616199.
NRAS mutation is present in 15–20  % of all melano-
mas, characterized by poorer prognosis, with no targeted 
agents yet available. Nevertheless, these patients may 
respond better to immunotherapy, including high-dose 
interleukin 2 (IL-2) [22], and checkpoint inhibitors such 
as anti PD-1/PD-L1 drugs [23]. Binimetinib (MEK-162), 
an oral selective MEK 1/2 inhibitor, is currently under 
development together with other MEK-inhibitors, alone 
or in combination. MEK-162 has shown clinical activ-
ity in NRAS-mutated melanoma, with 63  % of disease 
control rate and 10  % of confirmed partial responses 
[24]. Combination of a MEK-inhibitor with a CDK4-
inhibitor showed promissing results in patients with 
NRAS-mutated melanoma. The combination of oral 
selective inhibitors of MEK 1/2 (binimetinib) and CDK 
4/6 (LEE011) has been tested in a phase IB/II study to 
block MAP-K signaling pathway at two downstream lev-
els of RAS pathway [25]. Preliminary results on the first 
21patients with MM showed an 86 % clinical benefit rate, 
often with early tumor shrinkage and major symptoms 
improvement. Patients remaining on study had an expo-
sure to the study drugs ranging from 2 to 8 months. Com-
mon treatment-related adverse events included elevated 
serum CPK and creatinine, fatigue, skin, haematologic 
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and gastrointestinal events. Combination treatment 
often required dose interruptions and reductions due 
to adverse events. The maximum tolerated dose (MTD) 
for the current dosing schedule was determined to be 
200 mg/daily (3 weeks on-1 week off schedule) of LEE011 
and 45  mg/bid (continuous schedule) for bimetinib. 
Exploration of intermittent schedules to improve toler-
ability and further analysis of effect of additional genetic 
alterations on clinical outcomes are underway.
The PI3K (phosphatidylinositol 3-kinase)-AKT path-
way is a critical regulator of many essential physiological 
processes involved in cancer, including cell proliferation, 
apoptosis, motility, angiogenesis and metabolism. There 
is increasing evidence that activation of this pathway 
plays a significant role in melanoma, frequently in the 
setting of concurrent activation of RAS-RAF-MEK-ERK 
signaling. The PI3K-AKT pathway can be activated in 
multiple ways in melanoma, with the two most com-
mon being activating NRAS mutations and loss of the 
PTEN tumor suppressor. Melanomas with loss of PTEN 
have higher AKT activation than NRAS mutations [26]. 
In lymphadenectomy specimens from BRAFV600 muta-
tion-positive patients with stage IIIB/C melanoma, com-
plete loss of PTEN expression correlated with shorter 
time to brain metastasis (but not metastases to the liver, 
lung or bone) and decreased overall survival [27]. PTEN 
loss was prognostic and predictive of brain metastasis 
specifically in BRAF V600-mutant melanomas. Brain 
metastases have also shown increased expression of sev-
eral activation-specific protein markers in the PI3K-AKT 
pathway compared with extracranial metastases, includ-
ing in paired tumors from individual patients [28].
In BRAF-mutant human cutaneous melanoma cells 
treatment-induced activation of AKT has been shown 
to mediate resistance to cell death by the MEK inhibitor 
selumetinib (AZD6244) [29]. Inhibition of AKT activ-
ity, either by AKT knockdown or concurrent treatment 
with the mTORC1/2 inhibitor AZD8055, resulted in 
synergistic cell killing in selumetinib-resistant cell lines. 
In another study, a subset of BRAF- and NRAS-mutant 
human melanomas resistant to selumetinib were identi-
fied that were characterized by elevated oxidative phos-
phorylation (OxPhos), mediated by the transcriptional 
coactivator PGC1α [30]. Selumetinib-resistant high 
OxPhos cell lines, but not low OxPhos cell lines, could 
be resensitized to MEK inhibition by co-treatment with 
AZD8055. In both BRAF- and NRAS-mutant melanoma 
cells, MEK inhibition increased microphthalmia-asso-
ciated transcription factor (MITF) expression, which in 
turn elevated levels of PGC1α. In contrast, mTORC1/2 
inhibition resulted in cytoplasmic localization of MITF, 
thereby decreasing PGC1α expression and inhibiting 
OxPhos. Combined targeting of the MAPK and mTORC 
pathways may be a potential personalized therapeutic 
strategy for melanomas with increased OxPhos.
BRAF V600 inhibitors such as vemurafenib and dab-
rafenib leading to the activation, of several mechanisms 
of resistance [31]. Compensatory/adaptive responses to 
targeted inhibitors are frequently initiated by the activa-
tion of growth factor receptor tyrosine kinases, includ-
ing ErbB3/Her3. ErbB3 is a potent activator of the PI3K/
AKT pathway that expression correlates with melanoma 
progression. The receptor tyrosine-kinase (RTK) array 
profiling demonstrated hyperactivation of pErbB3 recep-
tor in three different melanoma cell lines after treatment 
with vemurafenib. Enhanced pErbB3 signaling is accom-
panied by hyperactivation of pAKT and occurs also in 
cells exposed to a MEK inhibitor. These results suggest 
that enhanced ErbB3 signaling may serve as a mecha-
nism of adaptive resistance to RAF and MEK inhibitors 
in melanoma. This feedback survival loop is promoted 
by increased autocrine production of neuregulin (NRG1) 
that is a ligand for ErbB3. Treatment with vemurafenib 
increases neuregulin gene expression in several cell lines. 
These findings support the idea that NRG1 acting in a 
paracrine manner, promotes resistance to RAF inhibi-
tors and emphasize that targeting the ErbB3/ErbB2 path-
way will likely improve the efficacy of RAF inhibitors for 
mutant BRAF melanoma patients.
The use of the anti-ERrbB3 monoclonal antibody 
(MAb) A4 abrogates the BRAF inhibitor-induced feed-
back loop and potentiates the vemurafenib inhibition on 
melanoma cells growth. ErbB3 mAb treatment impairs 
the resistance to vemurafenib in WM266 melanoma cells 
and restores drug sensitivity to vemurafenib including 
BRAFi-resistant cell lines [32]. The combination of two 
mAbs recognizing distinct epitopes on the ErbB2/Her2 
receptor, has been shown to have a superior anti-tumor 
effect [33]. Similarly, the anti-ErbB3 A3 and A4 combi-
nation synergistically inhibits melanoma cells growth 
and accelerates ErbB3 targeting to lysosomal degrada-
tive pathway. It also abrogates both vemurafenib- and 
trametinib-induced ErbB3 activation and potentiates its 
inhibition of melanoma cells growth. A3/A4 mAbs com-
bination synergizes with vemurafenib and trametinib 
in the inhibition of cell growth and in the induction of 
apoptosis, and strongly reduces tumor relapse in  vivo 
after drug withdrawal.
The heat shock protein 90 (HSP90) family of chaper-
ones maintains the malignant potential of cancer cells 
by regulating the conformation, stability and function 
of many receptor tyrosine kinases (RTKs) required for 
oncogenic transformation. Many proteins required for 
melanoma initiation and progression, including mutated 
BRAF, CRAF, CDK4 and AKT are known to be clients of 
HSP90 family members. This information has provided 
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the rationale to use HSP90 inhibitors to overcome mech-
anisms of BRAF-inhibitor resistance. The glucose-regu-
lated protein 94 (GRP94) is HSP90 like protein in the ER. 
GRP94-specific mAb W9 that recognizes an extracellular 
epitope of this protein and is able to overcome the BRAF-
inhibitors resistance in human melanoma cell lines carry-
ing a BRAF-V600E mutation. It increases the sensitivity 
of BRAF-mutant melanoma cells to BRAF-inhibitors and 
restores the sensitivity of resistant melanoma cells to 
BRAF-inhibitors. MAb W9 is expected not to cause sig-
nificant side effects because it has limited or no reactivity 
towards normal tissues [34].
Immunotherapy combinations
Before the immuno-targeted era, patients with MM 
experienced a median PFS at 6  months of 15  % and 
1-year OS of 25  % [35]. However, in the immunother-
apy era initiated with high-dose IL-2 therapy durable 
responses, some in patients with large volume and vis-
ceral disease [36], as well as in BRAF mutant and wild-
type (WT) patients [22] were observed. Response was 
maintained in the off-treatment period, with 11  % of 
patients alive after 5  years from starting therapy. Ipili-
mumab showed a significant OS benefit in patients with 
either BRAF WT or mutant melanoma [37]. Moreover, 
BRAFi treatment was effective in patients with BRAF 
mutations who had received prior immune therapy [38, 
39] but the proof of efficacy in the opposite sequence is 
not available. Because of this sequence variability BRAFi 
therapy may not be the best initial therapy for patients 
with BRAF mutation [40, 41]. A restrospective analysis 
showed that overall survival in patients who received 
ipilimumab followed by a BRAFi seems to be longer 
than in patients who received the treatment in reverse 
sequence, irrespective of the presence of prognostic 
adverse features such as elevated LDH and brain metas-
tases [42]. However, prospective randomized data is not 
available to evaluated the two sequences. Current data 
suggest that for patients with BRAF mutation immuno-
therapy as initial treatment could offer long term benefit, 
without compromising the effect derived from subse-
quent BRAF-inhibitor therapy.
In the future, immunotherapy highly likely will be 
included in the therapeutic strategy in patients with 
BRAF-mutation, especially when better drugs and bio-
markers for patients’ selection will become available. 
Newer drugs such as nivolumab (NIVO) are approach-
ing the efficacy (ORR and PFS) of BRAF-inhibitors with 
more durability. Toxicity to BRAF-inhibitors, however, 
could be worse in patients who previously received 
immunotherapy. Severe adverse events were mainly der-
matologic, with some cases reported of acute renal fail-
ure due to interstitial nephritis and of liver failure.
Combination of immunotherapy with targeted therapy 
may provide synergistic benefit in the treatment of MM, 
due to an improvement of long-term survival as com-
pared to a single treatment. BRAF-inhibitors affect both 
the tumor and the immune cells in patients with mela-
noma. In the tumor, BRAFi have demonstrated potential 
to immunosensitize by up-regulation of melanoma dif-
ferentiation antigens (MDA) expression and the CD8+ 
T cell infiltrate whereas, in the immune system BRAFi 
reduced the level of immunosuppressive cytokines and 
increased PD-L1 expression [43]. When combining MEK-
inhibitor with a BRAF-inhibitor MEK inhibitors may 
influence the cytokine production and immunosuppres-
sive cell populations in the tumor microenvironment 
as observed in  vitro [44]. MEKi trametinib also signifi-
cantly improved the antitumor effect of BRAF inhibitor 
dabrafenib in combination with adoptive T cell transfer 
(ACT) and PD-1 blockade in BRAF V600E driven murine 
melanoma cells SM1 model [45]. Improved effector T 
cell homing to the tumors, increased MHC expression, 
cytokine release and attenuated immunosuppressive cells 
were observed in this study. These findings support test-
ing these drugs in combination with immunotherapy in 
patients with BRAF-V600E mutated MM clinical trials. 
VEMUPLINT is a phase I–II study evaluating safety and 
efficacy of vemurafenib in combination with PEG-inter-
feron in patients with BRAF-V600E mutation. Second-
ary objectives of this study are the IFN-alpha-receptor-1 
(IFNAR-1) up-regulation and identification of markers 
of response to this treatment. Preclinical data also sug-
gest the synergy of BRAF-inhibitors with anti-PD-1/
PD-L1. MPDL3280A, a human Fc optimized anti-PD-
L1 antibody (Roche), in combination with vemurafenib 
demonstrated promising activity in melanoma although 
with some grade 3 toxicity including rash and AST/ALT 
elevation [46]. Significant hepatotoxicity is also one of the 
major adverse events of vemurafenib in combination with 
anti-CTLA4 antibody ipilimumab [47]. In the phase I 
study combining dabrafenib +  ipilimumab ± trametinib 
in patients with BRAF V600E/K mutation, the authors 
showed that standard doses of dabrafenib (150  mg bid) 
and ipilimumab (3 mg/Kg) can be administered without 
any severe grade toxicity and with all evaluable patients 
having a reduction in the sum of lesion diameter [48]. 
Patients treated with trametinib in addition to dabrafenib 
and ipilimumab had a greater incidence of gastrointesti-
nal toxicity, with 2 patients having a grade 3 colitis and 
one patient with a grade 4 intestinal perforation [49].
Targeting the immune checkpoints (anti-CTLA-4, anti-
PD1/PDL1) has a critical role both in the priming and 
in the effector phase of the antitumor immune response 
[50]. After becoming the first agent to demonstrate a sig-
nificant OS improvement in a randomized phase 3 trial 
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in metastatic melanoma [51], the anti-CTLA-4 antibody 
ipilimumab was approved for this indication. In addi-
tion to CTLA-4, more other immune check-points are 
potential targets for immunotherapy. For example, inter-
action of the programmed death 1 (PD-1) receptor with 
its ligands (PD-L1/B7-H1 and PD-L2/B7-DC) in periph-
eral sites leads to T-cell inactivation and loss of effector 
function. Targeting this pathway using antibodies against 
PD-1 (e.g., nivolumab, pembrolizumab) or PD-L1/PD-L2 
prevents T-cell inactivation and restores immune activ-
ity directly at the tumour site [52]. Immunotherapies 
targeting other immune checkpoint molecules such as 
LAG3 are also under evaluation in advanced malignan-
cies, either as monotherapy or in combination. Phase 
I nivolumab trial enrolled more than 100 patients with 
solid tumors, showing long-term overall survival ben-
efit in all dose cohorts [53]. Patients with MM who 
received nivolumab 3.0 mg/kg q2w reached 20.3 months 
of median OS, with 32  % of patients who were alive at 
4  years following treatment initiation. An open-label, 
phase III trial randomized patients with MM to receive 
nivolumab 3  mg/kg q2w or chemotherapy at investiga-
tor’s choice (dacarbazine or carboplatin  +  paclitaxel 
q3w) until progression or unacceptable toxicity. Patients 
were stratified according to PD-L1 expression, BRAF sta-
tus and response to prior anti-CTLA4 therapy. Patients 
receiving nivolumab should be treated beyond progres-
sion if considered by the investigator to be experiencing 
clinical benefit and tolerating study drug. ORR, by central 
review, was threefold greater for nivolumab as compared 
with chemotherapy (32 vs. 11 %). In patients BRAF wild-
type and treatment-naive nivolumab experienced, in a 
phase 3 randomized study, significantly greater OS (pri-
mary endpoint) as compared with dacarbazine [54]. One-
year OS was 73 % in patients who received nivolumab and 
42 % in those treated with chemotherapy (HR =  0.42—
99 %CI 0.25–0.73; p < 0.0001). Response rate was more 
than doubled in patients treated with immunotherapy (40 
vs. 14 %). In the phase I combination trial of nivolumab 
plus ipilimumab best results in terms of both efficacy and 
safety have been obtained with the IPI 3 mg/kg q3w for 
4 doses + NIVO 1 mg/kg q3w for 8 doses schedule, fol-
lowed by maintenance with NIVO 3  mg/kg q2w for no 
more than 48 doses [55]. In this cohort median duration 
of response has been yet not reached; 94  % of patients 
were alive at 1 year after treatment and 88 % at 2 years. 
IPI activity could also be enhanced adding the granulo-
cyte/macrophage colony-stimulating factor (GM-CSF) 
sargramostim. In a randomized phase III trial the com-
bination IPI  +  GM-CSF significantly increase median 
OS as compared with IPI alone [56]. The monother-
apy arm has been characterized by more severe grade 
adverse events, especially gastrointestinal, probably due 
to a protective effect from sargramostim. A very impor-
tant challenge is to identify factors predicting clinical 
response to anti-CTLA-4. Some authors have tried to 
select somatic mutations in patients with MM respond-
ing to IPI [11]. They found that mutational load was only 
associated but not predictive of response and identified a 
neoantigen panel which was predictive of response to IPI. 
PD-L1 status seems not to be a predictive factor because, 
in patients with MM who received a fully human anti-
PD-1 mAb nivolumab (NIVO), OS was improved as com-
pared to dacarbazine irrespective of PD-L1 status.
Treatment of MM with anti-PD-1/PD-L1 antibodies 
such as nivolumab or pembrolizumab resulted in 40  % 
ORR as first-line therapy and 20–30 % post-ipilimumab, 
with 65–75  % of patients still alive at 1  year. Possible 
mechanisms for innate resistance to PD-1/PD-L1 block-
ade are insufficient or disfunctional tumor antigen spe-
cific T-cells in tumor microenvironment, loss of tumor 
antigen presentation or innate tumor cell resistance to 
immune-mediated killing. Multiple combinations based 
on PD-1/PD-L1 blockade are supported by animal mod-
els, although no human data are yet able to predict the 
best combination for any individual patient. PD-1 and 
CTLA-4 have different roles in T-cells differentiation 
and regulation in the tumor microenvironment. For 
these reasons, the double blockade strategy seems to 
be more efficacious as compared to the single blockade 
in reducing median tumor volume. Phase I CA209-004 
study evaluated, in different cohorts, the tolerability of 
nivolumab and ipilimumab given at different doses and 
as concurrent or sequencing schedule [55]. The cohort 
who reported the best efficacy/toxicity ratio was the 
sequencing schedule with nivolumab 1  mg/Kg  +  ipili-
mumab 3  mg/Kg every 3  weeks for 4 cycles followed 
by nivolumab 3 mg/Kg every 2 weeks for no more than 
48 cycles. This schedule reported 44  % ORR (with 7  % 
CR) and 29 % of patients had at least 80 % reduction in 
tumor burden at 36  weeks. Responses were obtained in 
50 % of patients with BRAF mutations and in 37 % with 
wild-type status. Almost 2/3 of patients in this cohort 
experienced at least one grade 3–4 adverse event, mainly 
rash, diarrhea and ALT or lipase increase. Treatment-
related, immune-mediated, severe grade adverse events 
in this cohort were mainly skin (17  %), gastrointestinal 
(20  %) and hepatic (12  %). Questions to be addressed 
about the anti-PD-1/PD-L1+ anti-CTLA4 combination 
therapy concern what is the best schedule (concurrent 
vs. sequential), the management of adverse events, the 
search for predictive biomarkers and the safety of triple 
combinations. However, if phase III trials will confirm 
early data, the combination of an anti-PD-1+ an anti-
CTLA-4 could become standard of care in patients with 
MM, in both BRAF WT or mutated status.
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Use of vaccines that stimulate strong immune 
responses against the specific targets in combination 
with drugs that can inhibit the immune-suppression of 
T-cells could be one of the promising strategies to opti-
mize immunotherapy in MM. Drugs such as anti-PD-1 
antibodies and low-dose chemotherapy with cyclophos-
phamide (LD-CPM) that targets T regulatory (Treg) 
cells with minimal effect on other T-cell populations 
[57] could be the optimal candidates for the combination 
therapies. Further, anti-PD1 antibodies and LD-CPM are 
able to synergistically decrease and maintain low level 
of Tregs infiltration in the tumor and in the periphery. 
Addition of the vaccine to this combination enhances 
the level of tumor-infiltrated CD8+ T-cells and of CD8/
Tregs ratio in tumor microenvironment thereby promot-
ing tumor rejection. Clinical phase II trials utilizing this 
combination of anti-PD1, LD-CPM and vaccines are cur-
rently undergoing in prostate and pancreatic cancers as 
adjuvant therapy.
PD-1 can also be targeted using a recombinant protein, 
B7-DC-Ig. This is composed of an extracellular domain 
of murine B7-DC, a PD-1 ligand fused to Fc portion of 
murine IgG2a. B7-DC-Ig has been shown to enhance 
the therapeutic efficacy of vaccine when combined 
with cyclophosphamide. The combination significantly 
enhanced the Ag-specific immune responses, leading to 
the complete eradication of established tumors in 60  % 
of mice and the effect was observed to be CD8-depend-
ent [58]. It is also important to determine the optimal 
scheduling of various immunomodulators in combina-
tion therapies. For example, B7-DC-Ig was more effective 
when administered in a sequential schedule with cyclo-
phosphamide and vaccine as compared to a simultaneous 
schedule in a CD4-dependent model. Further, B7-DC-Ig 
showed an antitumor effect only when administered at 
the end of the schedule. Similarly, anti-PD-1 exhibits pro-
longed survival only when given together with vaccine.
In addition to inhibitory strategies, T-cells stimulators 
such as OX40 can also be used in combination therapies 
for cancer. OX40 (CD134) is a tumor-necrosis factor 
receptor (TNFR) that is mostly expressed on activated 
T-cells (both CD4+ and CD8+) and transmits a potent 
co-stimulatory signal when activated. OX40 enhances 
T-cell responses and is associated with increased T-cell 
expansion and proliferation, survival, and memory devel-
opment. Anti-OX40 antibody is a T-cell stimulator, which 
can be considered as a promising anticancer approach in 
combination with vaccines. In fact, treatment of tumor 
bearing mice with an anti-OX40 agonist antibody in 
combination with a specific vaccine showed an enhance-
ment of antigen-specific T-cells responses [59].
Tumor cells are able to produce a number of suppres-
sive signals as a protective mechanism against their 
destruction, such as increased expression of indoleam-
ine-(2,3)-dioxygenase (IDO). IDO is an important 
enzyme in the tryptophan metabolism and is shown to 
downregulate activating natural killer cell receptors on 
NK cells and also to inhibit cytotoxic T cells (CTL) [60]. 
Therefore, it has been targeted with an inhibitor, 1-meth-
yltryptophan (1-MT) for cancer therapy.
In conclusion, combination therapies that target 
immune-inhibitory and immune-suppressive molecules 
as well as stimulate immune-stimulatory molecules have 
been developed and investigated. The biological effects of 
combination immune therapies are, however, dependent 
on several factors such as the biology and mechanisms, 
dose, sequence, and timing of the specific agents as well 
as the type of effector response, which need to be care-
fully considered for optimum therapeutic effects.
Other combination approaches
Ionizing radiations have pro-immunogenic effects at mul-
tiple levels. Immunostimulation achieved by combining 
immunotherapy with localized radiation can lead to the 
so-called abscopal effect, consisting of tumor response 
outside the radiation field. Patients with an abscopal 
response are more likely to be already more immuno-
competent, with preclinical and clinical data supporting 
this feature because abscopal effect seems to be abro-
gated in nude mice [61] and in patients with high ratio of 
circulating neutrophils/lymphocytes [62]. The hypothesis 
which supports the synergistic effect of radiotherapy in 
combination with immunotherapy is that ionizing radia-
tions can stimulate anti-tumor immunity by generating 
an in situ vaccine, and combination with immunotherapy 
may enhance this effect.
Radiation therapy (RT) also modifies the immune sys-
tem interaction with cancer, driving the tumoral tis-
sue from a lymphocyte-poor to a lymphocyte-enriched 
environment [63]. In part, this effect is the result of RT 
upregulation of chemokines, seen in multiple mouse and 
human cancer cells, which enhance CD8+ T-lympho-
cytes recruitment and tumor infiltration [64]. The RT 
also upregulates retinoic acid early inducible-1 (RAE-1), 
a ligand for natural killer (NK) cell group 2D (NKG2D) 
receptor (RAE-1). RAE-1 stabilizes the immune synapses 
between CD8+ T-lymphocytes and target tumor cells 
promoting the killing activity of anti-CTLA-4 antibody-
activated T cells [65].
Pre-clinical evidence shows that the magnitude of anti-
tumor CD8 T cell responses activated by the combina-
tion of RT and anti-CTLA-4 treatment is dependent on 
the availability of dendritic cells (DCs) in the tumor and 
draining lymph nodes. In a mouse model of triple nega-
tive breast cancer type I or invariant NK (iNKT) cells, 
which are CD1d-restricted T-lymphocytes recognizing 
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lipid antigens presented by DCs, regulate DCs numbers 
limiting the efficacy of treatment. INKT-deficient mice 
have significantly more DCs in the tumor and drain-
ing lymph nodes and show evidence of some spontane-
ous anti-tumor immunity. Response to treatment with 
CTLA-4 blockade and RT is markedly improved in mice 
lacking iNKT cells or treated with an antibody blocking 
their interaction with DCs by binding to CD1d [66, 67].
Another critical factor that determines the efficacy of 
RT with anti-CTLA-4 antibody is the radiation regimen 
employed. While radiation-induced immunogenic cell 
death in  vitro is dose-dependent [68], in  vivo three to 
five fractions of 6 or 8 Gy are more effective than a sin-
gle 20  Gy dose in inducing immune-mediated rejection 
of the irradiated tumor and non-irradiated synchronous 
tumor in combination with anti-CTLA-4 [69].
Confirming results obtained in preclinical studies [70], 
addition of radiation to one tumor site was shown to 
induce systemic responses (abscopal effects) in patients 
with melanoma resistant to anti-CTLA-4 treatment 
alone [71]. A similar synergy of radiation with anti-
CTLA-4 was reported in a patient with lung cancer, a 
tumor type previously shown to be unresponsive to sin-
gle agent anti-CTLA-4 [72]. Multiple clinical trials test-
ing the activity of RT in combination with ipilimumab 
in solid tumors are ongoing. Results of a randomized, 
double-blind, placebo-controlled phase III study of ipili-
mumab plus palliative bone RT (8 Gy in single fraction) 
in patients with metastatic, castration-resistant, pros-
tate cancer who have progressed after docetaxel have 
been recently published [73]. The study was powered to 
detect a 4-month difference in median overall survival 
between the two arms but failed to meet its primary 
endpoint. Survival curves initially favored the placebo 
arm but, after 6  months, they split showing an evident 
advantage for patients who received ipilimumab. In the 
experimental arm, the 6-months PFS was 30.7 % as com-
pared with 18.1  % in the placebo arm. Possibly, factors 
like the inclusion of patients with visceral metastasis, the 
choice of bone metastasis as radiation target, and a sin-
gle dose fractionation may explain the limited success of 
the combination in this trial [74].
Other immune response modifiers have shown syn-
ergy with RT. Imiquimod (IMQ) is a synthetic toll-like 
receptor 7 (TLR7) agonist approved in the US as a topical 
cream for treatment of superficial basal cell carcinoma, 
external genital warts and actinic keratosis. In the prim-
ing phase, the activation of TLR7 leads to the activation 
of T-helper-1, B lymphocytes and natural killer cells. 
IMQ has shown some activity in patients with cutaneous 
breast cancer metastases [75, 76]. In preclinical studies, 
the combination of topical IMQ and RT was more effec-
tive than each agent used alone and induced abscopal 
effects [75]. A clinical trial is currently ongoing to test 
this combination in the clinic.
The anti-TGF-beta antibody fresolimumab has also 
been tested in combination with RT in metastatic breast 
cancer (NCT01401062). Median OS and PFS appeared 
to be better in patients treated with fresolimumab at 
10 mg/dose as compared with those who received 1 mg/
dose. Preclinical studies demonstrate that TGF-β, which 
is activated by RT, is a dominant immunosuppressive 
barrier precluding the generation of an effective in  situ 
tumor vaccination by RT [77].
Overall, preclinical and clinical evidence suggests that 
local radiotherapy can help the efficacy of cancer immu-
notherapy, by rendering the irradiated tumor more 
immunogenic. Radiotherapy can be harnessed as an adju-
vant to immunotherapy as it may convert non-respond-
ers patients to responders to the same immunotherapy. 
Dose fractionation and sequencing of radiotherapy need 
to be explored in combination with each immunotherapy 
strategies, in prospective clinical trials. Many questions 
remain to be addressed in this field, regarding the opti-
mal sequencing of radiotherapy and immunotherapy, 
the best dosing and fractionation schedule and patients 
selection. There is also a lack of data about the optimal 
site to be irradiated in metastatic disease, in order to 
obtain the best immunological response.
Tumor vaccines that consist of strategies that intend to 
prime and boost specific immune responses in a tumor 
bearing host can be combined with immunostimulatory 
mAb in clinical trials [78]. Virotherapy has been devel-
oped in gene therapy, using viruses as vectors for genes 
encoding vaccines and antitumoral transgenes. Semliki 
Forest Virus (SMV) has been used as a vector to express 
IL-12, which than can be injected into subcutaneous 
tumors-bearing mice. In melanoma model, the antitu-
mor activity of SFV-IL-12 vector given intratumorally 
can be enhanced adding an agonist antibody to CD137 
costimulatory receptor on T cells given systemically [79]. 
This is also true with anti-PD-1 mAbs [80]. CD8+ cells 
are the main mediators of the curative response. This 
efficacious combinatorial immunotherapy strategy offers 
feasibility for clinical translation since anti-CD137 mAbs 
are already undergoing clinical trials and development of 
clinical-grade SFV-IL-12 vectors is in progress.
According to the final report of the study compar-
ing sentinel-node (SN) biopsy vs. nodal observation in 
patients with melanoma, SN provide very important 
prognostic information and help to identify patients 
with nodal metastasis whose survival can be pro-
longed by immediate lymphadenectomy [81]. SN biopsy 
improves overall survival as compared to observation 
(HR = 0.54—95 % CI 0.37–0.80, p = 0.0017). The num-
ber of excised lymph nodes seems to be very important 
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in determining melanoma-specific survival. A retrospec-
tive review of 2536 patients showed the best survival in 
patients with more than 30 lymph nodes removed and 
the worse in those with less than 10 lymph nodes excised 
[82]. No difference on survival has been detected in 
patients with 10–30 lymph nodes excised. Multiple single 
institution series indicate long-term survival (22–23 % at 
5 years) following resection of multiple distant metasta-
ses for melanoma [83–87]. Prognostic factors in surgi-
cally resected stage IV melanoma have been identified in 
clinical trials [88–91] including:
  • ability to achieve complete surgical resection of all 
visible disease
  • tumor-doubling time
  • number of metastatic lesions (solitary vs. multiple)
  • disease-free interval (>36 vs. ≤36 months)
  • site of recurrence (brain vs. liver vs. lung or regional 
lymph nodes)
Electrochemotherapy (ECT) allows the permea-
tion into cancer cells of poorly permeable antineoplas-
tic drugs, such as bleomycin or cisplatin that allow for 
optimal concentration in the tumor tissue. ECT could 
be useful in treating cutaneous melanoma with curative 
intent or as neoadjuvant therapy to obtain shrinkage of 
the tumor. ECT may thus be used in the management of 
the tumor and less invasive surgery. Multiple treatments 
are possible, with about 75  % of overall response rate 
and 21.7 % of long-lasting response [92]. Electrochemo-
therapy seems also to be effective in combination with 
ipilimumab (IPI), with 60 % of disease control rate and a 
decreased Treg values in responders patients [93].
News in immunotherapy
Tumor antigen-specific CD8+ T cells in the periphery 
and at the tumor site co-express a number of inhibitory 
receptors including PD-1, BTLA and Tim-3. These inhib-
itory receptors are upregulated upon T cell activation and 
are often co-expressed by dysfunctional CD8+ T cells in 
the periphery and at tumor sites. We have observed that 
tumor antigen-specific CD8+ T cells co-expressing PD-1 
and Tim-3 are highly dysfunctional in terms of prolif-
eration and cytokine production while PD-1+BTLA+ 
Tim-3− CD8+ T cells appear less dysfunctional [94, 
95]. In sharp contrast, we also observed that PD-1+ 
BTLA− Tim-3− tumor antigen-specific CD8+ T cells 
are functional T cells, supporting that PD-1 is an activa-
tion marker that is also upregulated together with other 
inhibitory receptors by tumor antigen-specific CD8+ T 
cells upon chronic antigen activation. Interestingly, dual 
PD-1/BTLA and PD-1/Tim-3 blockades were superior 
to each single blockade in enhancing the expansion and 
function of tumor antigen-specific CD8+ T cells in vitro. 
Altogether, our findings support the use of dual PD-1/
BTLA blockade and dual PD-1/Tim-3 blockade to fur-
ther augment the expansion and functions of spontane-
ous CD8+ T cell responses to tumor antigens in patients 
with advanced melanoma.
In the context of a vaccine trial with CPG and MHC 
class I and class II peptides from the tumor antigen NY-
ESO-1, we observed that patients with advanced mela-
noma immunized with CPG, MHC class I and MHC 
class II epitopes developed higher frequencies of vaccine-
induced CD8+ T cells with lytic capacities as compared 
to patients immunized with CPG and MHC class I pep-
tide alone [96]. Interestingly, vaccine-induced CD8+ 
T cells upregulated PD-1 in their large majority while a 
minority co-expressed PD-1 and Tim-3. We also show 
that dual PD-1/Tim-3 blockade further enhanced the 
expansion and functions of the vaccine-induced CD8+ 
T cells in vitro. These data strongly support combinato-
rial therapies with cancer vaccines and PD-1 blockade 
to prime and expand potent CD8+ T cell responses in 
patients with advanced melanoma. Such approach may 
be beneficial to melanoma patients with no/poor sponta-
neous T cell responses to melanoma and who may be less 
likely to respond to PD-1 blockade alone.
Another target of interest in the tumor microenviron-
ment is the IL-10/IL-10R pathway. IL-10 receptor (IL10R) 
is a marker of T cell activation that is upregulated by PD-
1high CD8+ TILs and by tumor antigen-specific CD8+ T 
cells upon PD-1 blockade [97]. We observed that IL-10 
acts directly on T cells to induce the apoptosis of PD-1high 
tumor antigen-specific CD8+ T cells. Dual IL-10R/PD-1 
blockade enhanced the expansion and functions of tumor 
antigen-specific CD8+ T cells in patients with advanced 
melanoma. Such combinatorial approach warrants fur-
ther exploration in the clinic.
Tumor-associated antigen such as MAGE-A1 and 
mutated CDK4 identified by the “classical” method of 
CTL-guided molecular cloning are well known in mela-
noma. Deep sequencing has revealed that melanoma dis-
plays a very high frequency of non-synonymous somatic 
mutations. CD8 T cell reactivity against patient’s-spe-
cific somatically mutated antigens have been recently 
reported, in the context of immune checkpoint blockade 
therapy [98]. The CTL/Treg ratio is an important factor 
in determining the success of tumor immune responses 
and is an independent prognostic factor [99]. The role 
of the antigen-specific effector T cells (Teff)/Treg ratio, 
its functional outcome, and the potential of manipulat-
ing this balance by vaccination remains understudied. 
Some authors have tried to determine the role played 
by the type of adjuvant vaccine in modulating the tumor 
antigen-specific Teff/Treg response. Teff accumulation 
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among TIL depends on the adjuvant vaccine used and 
correlates with tumor protection. Moreover, the Teff/
Treg ratio in tumor-draining lymph nodes correlate 
with CTL infiltration in the TIL in the tumor site and 
enhanced the tumor growth control. Tumor vaccines 
such as CpG and Poly(I:C) induce inflammation and a 
rapid production of Th1 cytokines in the vaccine drain-
ing LN. They also dramatically increase the antigen-spe-
cific Teff/Treg ratio in the lymphoid organs, skewing the 
immune response in favour of a functional anti-tumor 
effect [100]. This study suggests that choice of the adju-
vant is important for peptide vaccine efficacy. Also, that 
Teff:Treg ratio can serve as biomarekrs predicting the 
vaccination outcome.
Moreover, micro-RNA expression profiling identified a 
limited set of differentially expressed microRNAs includ-
ing miR-21, miR-17 to 92, miR-146a/b and miR-155 
in primary human (and murine) CD8 T cells, suggest-
ing a role in CD8 differentiation and/or function [101]. 
miR-155 is upregulated in  vivo in differentiated mouse 
CD8 subsets, promoting CD8-T cells proliferation [102]. 
miR-155 expression is necessary for efficient CD8 T cell 
responses to virus, vaccination and cancer and is impor-
tant for accumulation but not differentiation of effec-
tor CD8 T cells. Of note, miR-155 deficient mice have 
impaired memory CD8 T cells and the mechanisms lead-
ing to this impairment remain to be identified. Prelimi-
nary results suggest that miR-155 expression levels are 
higher in the tumour infiltrated tissues than in non infil-
trated ones in malignant melanoma cancer patients. In 
addition, miRNA-155 overexpression in tumor-specific 
CD8+ T cells substantially increased their potency (Mar-
tínez and Romero unpublished), thus providing strong 
evidence for a clinical potential in the context of thera-
peutic adoptive T cell transfer.
One of the most common immune escape strategies 
carried out by tumor cells is altered signaling at different 
levels or immune response mechanism. Loss or down-
regulation of HLA antigens has been frequently observed 
in melanoma cells with increased frequency of deficien-
cies in metastatic cells vs. primary lesions. Alterations in 
the tumor cell surface expression of the HLA class I anti-
gens are often associated with the ability of cancer cells to 
escape from the antitumor immune response. Impaired 
HLA antigen expression is associated with a worse prog-
nosis and reduced survival of patients.
There are frequent aberrations in the expression of 
components of the antigen-presenting machinery in 
melanoma lesions as a result of down regulation at the 
transcriptional, epigenetic and posttranscriptional level 
or structural alterations, including deletions/mutations 
and polymorphisms. Micro-RNAs (miRs) are about 
22 nt long non-coding RNAs that are key mediators of 
post-transcriptional processing. In tumors, they control 
many processes such as apoptosis, proliferation, migra-
tion, immune responses and are associated with neoplas-
tic transformation, disease progression and poor patients’ 
outcome. Transporter Associated with Antigen Process-
ing 1 (TAP1) is an HLA class I processing machinery 
component that is regulated or even directly targeted by 
specific miRs species in tumor cell lines including mela-
noma. Another feature is also an impaired response to 
IFN due to a link between the IFN signaling and the HLA 
expression. Different mechanisms of IFN resistance as 
well as the induction of an immune tolerance could be 
demonstrated in melanoma cells. JAK-2 kinase gene dele-
tion on chromosome 9 has often been reported in IFN-γ 
resistant melanoma cells. JAK-2 deficient melanoma cells 
have a reduced expression of the antigen-presenting sys-
tem components, a mechanism that can be reversed with 
JAK-2 overexpression [103]. Similar results have been 
shown for STAT-1 (unpublished data).
Adoptive cell therapy (ACT) is an effective treatment 
for patients with metastatic melanoma. Adoptive cell 
therapy with tumor infiltrating lymphocytes (TILs) using 
IL-2 shows objective responses in about 50 % of patients 
in clinical trials [104], with a 20 % of complete responses. 
In a series of three consecutive clinical trials using 
increasing lymphodepletion before infusion of autolo-
gous TILs, objective response rates between 49 and 72 % 
were seen. Responses occur at all sites and appear to be 
durable with many patients in ongoing response beyond 
3  years. Mean telomere lenght, the number of CD27+/
CD8+ cells and the persistence of the infused cells in 
peripheral blood at 1  month after cell infusion are sig-
nificantly different in objective responders (CR  +  PR) 
as compared with non-responders [105]. In another trial 
using TILs and non-myeloablative lymphocyte-depleting 
chemotherapy in patients with MM, a shorter duration 
of expansion and infusion of more CD8+ cells is asso-
ciated with better clinical outcomes [106]. TILs from 
responder patients also contain more CD8+ cells, while 
quantities of CD4+ cells did not affect clinical outcomes 
[107]. Some efforts are ongoing in order to produce more 
potent TILs or to expand their intratumoral infiltration 
in patients with MM. Examples are the co-stimulation 
through the 4-1BB/CD137 antibody, which increases 
the CD8+ T cells frequency [108], and the use of K562-
derived artificial APCs, which acta s feeder cells for 
T-lymphocytes expansion [109].
Among methods to improve adoptive T-cell therapy 
following non-myeloablative chemotherapy, the admin-
istration of checkpoint inhibitory antibodies activating 
T cells or depletion of MDSCs in order to reduce immu-
nosuppression are proposed. Another method is re-stim-
ulation of the injected TILs with a tumor vaccine (e.g., 
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dendritic cells based) expressing the same antigen as rec-
ognized by TILs to improve life-span of the antigen spe-
cific T cells. MAT-02 is an ongoing clinical trial using the 
approach of combining TIL infusion with vaccination of 
autologous-lysate-loaded DCs, an approach which in an 
earlier pilot trial MAT-01 was feasible and demonstrated 
some clinical responses [110]. MDSCs in different cancer 
types are associated with different phenotypes (granulo-
cytic or monocytic). Monocytic cells CD14 + HLA-DR- 
MDSC (so-called mo-MDSC) numbers are greatly 
increased in melanoma patients and strongly suppres-
sive of T-cells proliferation and IFN-γ production [111]. 
Mo-MDSC are also suppressive for NK cells activity and 
can impair the quality of dendritic cells [112, 113]. Stud-
ies of the mechanisms involved in MDSCs induction 
and suppressive activity in melanoma patients is ongo-
ing. MDSCs represent potentially a new target for cancer 
immunotherapy, especially in melanoma. Other strate-
gies to counterbalance tumor-driven immune dysfunc-
tion are reversing the oxidative stress in cancer patients 
by the administration of histamine and antioxidants (e.g., 
vitamin E), and arming T cells by gene transfer of anti-
oxidants enzymes such as catalase or thioredoxin [114]. 
In breast cancer, T cells transduced with a HER2 spe-
cific CAR-catalase can kill HER-2 positive breast cancer 
cells more efficiently while under oxidative stress con-
ditions (Ligtenberg et  al. submitted). Checkpoint spe-
cific antibodies blocking CTLA-4 or PD-1/PD-L1 affect 
both monocytic and granulocytic MDSC’s. Monitoring 
the immune system during treatment with ipilimumab, 
showed a reduction in frequency of granulocytic MDSCs 
and Tregs, often after just one dose, both in responders 
and non-responders patients [115]. The predictive value 
of the change in decrease of these cell subsets for the 
therapy outcome, however, remains to be determined.
A particular kind of T cell, expressing the so-called 
Chimeric Antigen Receptor (CAR) and directed to CD19, 
have demonstrated very high activation ligand affinity 
and are very effective in treating hematological tumors 
such as acute lymphocytic leukemia [116] and B cell 
lymphoma [117]. Anti-CD19 CAR T cells remain in the 
circulation for approximately 28 days and greater quan-
tities of circulating CAR T cells are associated with bet-
ter clinical responses. However, treatment with CD19 
CAR T cells has been associated with a peculiar toxicity 
profile which is characterized by tumor lysis syndrome, 
cytokine-release syndrome (CRS) and neurotoxicity. 
Cytokine-release syndrome is a potentially life-threat-
ening toxicity which can be observed following admin-
istration of antibodies and adoptive T-cell therapies for 
cancer. CRS is typically associated with high circulat-
ing levels of cytokines such as IL-6 and IFN-gamma, 
and can be managed with corticosteroids or the use of 
tocilizumab, an anti-IL-6 antibody. The use of tocili-
zumab and steroids should be limited only to the poten-
tially life-threatening cases, since they may limit the 
effectiveness of the immunotherapy [118]. CRS is more 
likely to occur in patients with greater tumor burden and 
greater quantities of circulating CAR T cells. High serum 
level of IL-6, IFN-gamma and C-reactive protein are 
associated with more severe toxicity.
Tumor microenvironment and biomarker
In 1863, Virchow first described leukocytes in malignant 
tumors, believed to be “cells of origin” of cancer. Tumor-
infiltrating lymphocytes (TILs) have been cited by Ehr-
lich (in 1909) as host response to tumor. More recently, 
TILs have been associated with favorable prognosis 
in cancer patients, acting as a background for modern 
therapies such as targeted therapy and immunotherapy 
[119]. A widespread TILs diffusion in primary melanoma 
is associated with prolonged survival and reduced risk of 
metastasis. In lymph node metastasis, high amount of 
TILs improve survival as compared to lesions with low-
to-absent TILs infiltrates. Radial growth phase of primary 
melanomas commonly show lymphocytes that can cause 
partial tumor elimination. Cytolytic immune responses 
against autologous tumors in melanoma patients support 
the idea that TILs play a key role in immunologic tumor 
clearance. Tumor-reactive cytotoxic T lymphocytes in 
the blood, lymph nodes, and in lymphocytes infiltrate 
primary tumors and metastatic nodules of many can-
cer patients. Clonal CTL expansions have been identi-
fied in primary and metastatic melanomas undergoing 
spontaneous regression. These immune effector popula-
tions were found capable of cytotoxicity against autolo-
gous cancer cells. Adoptive transfer of autologous TILs 
in combination with IL-2 treatment resulted in tumor 
regression in metastatic melanoma. Prolonged survival 
by TILs have also been demonstrated in other cancers 
such as ovarian and colorectal.
The classic approach to TILs as a prognostic indicator 
utilized the “brisk/non-brisk” system, developed by Clark 
[120]. “Brisk” indicates when the entire base of the tumor 
is infiltrated by TILs (peripheral) or when TILs diffusely 
meet the tumor (diffuse). “Non-brisk” is when isolated, 
multifocal and segmental TILs infiltrate the tumor. 
“Absent” is when no lymphocytes are directly apposed 
to tumor cells. In a retrospective series of 285 cutaneous 
melanomas, “brisk” feature was associated with the best 
overall survival as compared with “non-brisk” or “absent” 
TILs. 5-years survival rate was 77  % in patients with 
“brisk” infiltration as compared with, respectively, 53 and 
37 % in “non-brisk” and “absent”. These results have been 
confirmed by preliminary data from the EORTC trial, 
involving 1260 patients with advanced melanoma and 
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still under further statistical analysis by Dr. Phyllis Gimo-
tty (University of Pennsylvania). The “brisk” peripheral 
pattern was associated with the best prognosis, especially 
in lesions >4 mm thickness, while the “non-brisk” periph-
eral pattern had the worse outcome. Impact of TILs on 
survival appears to be greater when there is no ulceration 
in the melanomatous primary lesion. TILs density can be 
scored according to the number of lymphocytes detect-
able per high power field (HPF): grade 1 (no more than 
10 ×  HPF), grade 2 (11–20 ×  HPF) and grade 3 (more 
than 20 × HPF). Patients with grade 3 TILs density are 
associated with better overall survival as compared to 
the lower scores [1]. The “brisk” peripheral pattern is 
also known as the advancing edge of the tumor, and the 
EORTC study emphasizes its significance as a prognostic 
factor.
Three other studies support the importance of the 
advancing edge. Phospho-ERK (pERK) and Ki67 expres-
sion seem to be good prognostic factors in patients 
with stage I/II melanomas. pERK low (less than 20  %) 
and Ki67 low (score less than 94) phenotype has better 
survival and time to development of metastasis as com-
pared with pERK and Ki67 high scores. SOX2-positive 
melanomas were significantly associated with a greater 
likelihood (twice as likely on average) of being 1  mm 
thicker than their SOX2-negative comparator. SOX2 
expression correlated with primary tumor thickness in 
survey cohort (OR = 2.01 [1.04, 3.92], p = 0.039). SOX2 
positive cells in patient melanomas are concentrated at 
the interface of tumors and the surrounding stroma and 
are observed in association with peritumoral vessels. 
SOX2 knockdown impairs melanoma cell invasion and 
co-localize with MMP-3 at infiltrative borders of patient 
melanomas [121]. Tumorigenic melanoma cells in sphe-
roids or nodules strongly and diffusely express nestin. In 
infiltrative tumor cells at margin, the nestin is restricted 
to the subplasma membrane region of the cell. This dis-
tribution in human melanoma cells and experimental 
animals is associated with EMT with fusiform cell shape, 
increase in MMP, invasion, and multiple FAK attach-
ment sites [122].
In most studies, there are tumors that do not show any 
response to TILs. A possible explanation for this immune 
evasion include Tregs failure. Tregs are 5–10 % of murine 
and human CD4+ T cell. They suppress CD4+, CD8+ 
T-cell, and NK cell responses and negatively regulate 
immune responses in vivo. Tregs deficiency is associated 
with massive T cell lymphoproliferation and multi-organ 
autoimmune disease (IPEX-human), characterized by 
immune dysregulation, polyendocrinopathy, enteropathy, 
and X-linked inheritance. Percentage of Tregs in patients 
with epithelial malignancies is more than doubled as 
compared with patients without tumors. Tregs removal 
also evokes an effective anti-tumor immunity in experi-
mental models.
In conclusion, TILs apparently play an important role 
in determining the progression of malignant melanoma. 
In many situations, however, TILs appear to be inef-
fective. Manipulation of the immune system, based on 
understanding of T cell function and natural immune 
checkpoints gives great hope for further improve survival 
in malignant melanoma.
Lymphatic mapping and sentinel node biopsy (LM/
SNB) for melanoma was first described 30  years ago. 
Two major worldwide clinical trials have been under-
taken. MSLT1 enrolled 2001 patients who were randomly 
assigned to wide excision and nodal observation, with 
lymphadenectomy for nodal relapse (observation group), 
or wide excision and sentinel-node biopsy, with immedi-
ate lymphadenectomy if nodal metastases were detected 
on biopsy (biopsy group). MSLT1 has been completed 
and definitive 10-years follow-up results were published 
last year [81]. Biopsy-based management improved the 
10-year rate of distant disease-free survival (hazard ratio 
for distant metastasis, 0.62; p  =  0.02) and the 10-year 
rate of melanoma-specific survival (hazard ratio for death 
from melanoma, 0.56; p = 0.006) for patients with inter-
mediate-thickness melanomas and nodal metastases. 
LM/SNB accurately stages regional nodes (95–97 % accu-
racy), identifies patients with clinically occult metastatic 
disease in their sentinel node who are candidates for 
immediate completion lymph-node dissection (CLND). 
During clinical observation small metastases in SN 
become detectable and may spread to additional nodes 
(3.2 vs. 1.4, p = 0.001); SN metastases may also spread to 
distant sites (HR = 0.62—p = 0.0152). The early lymph-
node surgery approach is associated with substantially 
less morbidity.
Although CLND is standard for patients with SNB 
metastases, MSLT1 data show that 88  % of patients 
with a single tumor-containing sentinel node will have 
no additional nodal metastases when the CLND speci-
men is examined by hematoxylin-eosin staining. If nodal 
metastases are limited to one or two sentinel nodes, SNB 
might be therapeutic as well as prognostic. The MSLT2 
trial was designed to examine this possibility. The under-
lying hypothesis is that CLND can be avoided in most 
patients with sentinel node metastases. MSLT2 has com-
pleted accrual and 10-year follow-up data are due in 
2019. The MSLT trials helped identify two major primary 
melanoma subgroups, with differing risks of develop-
ing nodal metastasis. The major risk of node metasta-
sis is affects tumors having ≥1  mm Breslow thickness 
or <1  mm with mitoses or ulceration. These patients 
should be considered for sentinel node biopsy. Patients 
with melanomas <1  mm Breslow thickness and neither 
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mitoses or ulceration have a low-to-absent risk of nodal 
metastases. They can receive more conservative treat-
ment, based on wide excision and clinical follow up. 
After SN biopsy, about 80 % of nodes are microscopically 
negative: such patients can be considered as optimally 
staged and receive follow-up only. False negativity of SN 
accounts for less than 5 % in experienced hands. The 20 % 
of patients with microscopically positive SN have to be 
considered for immediate CLND. However, since more 
than 80  % of patients treated by immediate lymphad-
enectomy showed tumor-negative non-sentinel nodes, 
surgical overtreatment is a concern. To identify patients 
receiving unnecessary CLND, authors have evaluated 
parameters such as the number of SN with metastases, 
the site, size and frequency of metastases and the per-
centage of node replaced by tumor. They also performed 
a molecular pathology assessment with gene expres-
sion microarrays (GEM), in order to develop potentially 
predictive gene signatures. They found that the amount 
and disposition of tumor in the SN can predict groups of 
patients at risk for non-SN tumor, tumor recurrence and 
death from melanoma. Main survival predictors were the 
sentinel node tumor burden (p =  0.0023), tumor diam-
eter (p = 0.0173), tumor depth of invasion from capsule 
(p = 0.0096), the number of metastatic foci (p = 0.0063) 
and extra-capsular extension (p  =  0.0148). Molecu-
lar pathology assessment showed significantly different 
gene expression profiles comparing SN metastases from 
patients with and without metastasis in non-SN. Authors 
developed two preliminary gene signatures: signature 
1 contains 22 over-expressed genes related to cell cycle 
control, adhesion and proliferation, which are up-regu-
lated in patients with metastasis-positive non-SN. In the 
signature 2 there are 22 genes related to host immune 
functions (activation, maturation of T, B lymphocytes 
and dendritic cells), which appear to be under-expressed 
and down-regulated in patients with metastasis-positive 
non-SN. These gene signatures, although preliminary, 
will likely enhance the accuracy of prediction of non-SN 
tumor status, identifying patients likely to benefit from 
CLND. This will spare many patients the morbidity of 
extended surgery and significantly reduce medical costs. 
More accurate staging will also identify patients at high 
risk of visceral metastases who may benefit from rela-
tively aggressive adjuvant therapy.
There are three major hypotheses to explain the molec-
ular mechanisms which explain the T cell-inflamed vs. 
non-T cell-inflamed tumor microenvironments. Ger-
mline genetic differences are hypothesized to occur at the 
host level, such as polymorphisms in immune-regulatory 
genes, that could set thresholds for activation of immune 
cells. At the tumor cell level, somatic differences leading 
to activation of distinct oncogene pathways vary between, 
and specific pathways could lead to T cell exclusion. The 
Wnt/β-catenin pathway has been identified as the first 
pathway that mediates immune exclusion and resistance 
to immunotherapies [123]. Preclinical data have also 
supported a role for the commensal microbiota impact-
ing on systemic anti-tumor immunity, and specific com-
mensal bacteria have been identified that can facilitate 
immune-mediated tumor control as a pro-biotic. Identi-
fying these factors is important, as T cell-inflamed tumor 
microenvironment may act as a predictive biomarker 
for response to immunotherapies. Most immunotherapy 
responders (vaccines, anti-CTLA-4, anti-PD-1) have a 
microenvironment characterized by high production 
of chemokines and a CD8+ T-cell infiltrate. The mecha-
nism of generation of a spontaneous anti-tumor immune 
response appears to be driven by the host STING/IFN- β 
pathway, activated by tumor- derived DNA acquisition 
by dendritic cells [124]. STING agonists may provide 
means to deliberately initiate innate immune inflamma-
tion to promote an endogenous T cell response in non-T 
cell-inflamed tumors. In multiple tumor models, intra-
tumoral injection of STING agonists promoted strong 
endogenous immune responses and triggered durable 
tumor rejections [125]. The host STING pathway is also 
necessary to obtain a therapeutic effect from radiation 
therapy in vivo [126], providing another means by which 
anti-tumor immunity can be facilitated.
Recently, the importance of the adaptive immune reac-
tion, in terms of nature, functional orientation, density 
and location within different tumor regions, as a coun-
terpart of tumor invasion has been recognized [127, 128]. 
However, the development of a simple and powerful clin-
ical test (“immunoscore”) based on the complex intra-
tumoral immune reaction has been a difficult challenge 
[129]. The immunoscore displays characteristics related 
to the adaptive immune response, with regard to the cell 
type (CD3+ and CD8+ T cells) as well as their density 
and location (intratumoral vs. margins) [130]. In order to 
be implemented into the human cancer classification and 
patients management i.e., determine patients risk and 
assign patient to specific therapy including immunother-
apy, respectively, the “immunoscore” needs to be analyti-
cally validated and undergo clinical validation process. 
So far the value of the immunoscore has been well estab-
lished in patients with early-stage (I–II) colorectal cancer 
where the immune profile seems have higher prognostic 
importance than clinical features such as TNM-staging 
system [131]. The process for immunoscore validation is 
currently ongoing worldwide using a standard operating 
procedure and an assay harmonization involving 23 cent-
ers in 17 countries. Prospective observational trial for 
clinical validation of the prognostic value of the immu-
noscore is currently ongoing (NCT01688232). In this 
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trial immunostaining for CD3, CD8, and CD45RO mark-
ers and high-resolution scanning of the stained slides and 
quantification of digital images (Definiens) is performed 
[132]. Genomic study of the tumor to assess the MSI sta-
tus, the presence of a KRAS and BRAF mutations will 
be conducted for the same patients. The MISIPI study is 
a clinical trial focused on the prognostic and predictive 
value of the immunoscore including CD3, CD8, CD20, 
FoxP3 and CD163 and PD-L1 in patients with advanced 
melanoma treated with Ipilimumab with the follow-up of 
2–3 years [133]. The immunoscore is evaluated in meta-
static lymph node tissue which are constitutively rich in 
CD3+ and CD20+ lymphocytes, and correlated it with 
outcomes and response to the treatment. Lymph nodes 
often are the unique site of metastatic disease and are 
more accessible to biopsy than distant metastasis [134]. 
Immunoscore (CD3, CD8, in tumor center and margin) 
has been evaluated the resected metastasis of 116 brain 
metastatic patients, supporting the major prognostic 
value of Immunoscore in brain metastasis. Immunoscore 
showed significant correlation with survival prognosis 
(27 vs. 10 months; p < 0.001). The prognostic impact of 
Immunoscore was independent from established prog-
nostic parameters at multivariable analysis (HR 0.612, 
p < 0.001) [135].
There are two ways to up-regulate PD-L1 expression in 
solid tumors: by constitutive, oncogenic signaling and by 
an adaptive, inducible mechanism, both of which may be 
operative in different tumor types. The concept of PD-
L1-mediated adaptive immune resistance was developed 
when the observation was made that PD-L1 expression 
in melanoma is often focal, and geographic, and almost 
always immediately adjacent to TIL. When this finding 
was explored further, it was apparent that while TILs 
are necessary, they are not sufficient for PD-L1 expres-
sion in melanomas, leading to the hypothesis that it was 
functional differences in TILs that accounted for the dif-
ferential PD-L1 expression by tumor cells [136]. When 
whole transcriptome analysis was performed comparing 
PD-L1+ vs. PD-L1(−) melanomas, functional groups 
of differentially expressed genes were observed, includ-
ing an IFN-gamma/Th1 signature, a CD8 T-cell signa-
ture, and numerous checkpoint molecules [137]. Taken 
together, these findings indicate that PD-L1 expres-
sion when observed adjacent to TIL reflects an adaptive 
immune resistance to an ongoing anti-tumor immune 
reaction. This mechanism is not dependent on the BRAF 
mutational status of the melanoma [138].
PD-1/PD-L1 blocking antibodies work by thwart-
ing this mechanism of adaptive immune resistance, and 
essentially protect the ongoing host immune response 
against tumor. Because the anti-PD-1/PD-L1 antibodies 
are thought to act locally within the tumor itself, PD-L1 
expression in pre-treatment tumor specimens has been 
explored as a possible “biomarker” to help predict which 
patients will respond to anti-PD-1/PD-L1 therapies. In 
a series of 49 patients with melanoma and other solid 
tumors, all clinical responders had PD-L1-expression 
on the surface of their tumor cells in their pre-treatment 
biopsies [138]. Similar results have since been shown in 
many other trials in multiple tumor types using anti-PD-1 
or anti-PD-L1. While it is now recognized that a pro-
portion of PD-L1 negative patients may also respond to 
these therapies, the objective response rate in PD-L1(+) 
patients exceeds PD-L1(−) patients 3–4 fold [139]. In 
ongoing clinical trials, PD-L1 expression in the tumor 
microenvironment is also being explored as it relates to 
progression-free survival and overall survival.
When other single factors in the tumor microenvi-
ronment such as PD-L1 expression by immune cells, 
expression of PD-1, CD4:CD8 ratio, and the presence of 
TIL were explored as markers of response to anti-PD-1, 
PD-L1 expression by tumor cells remained the strong-
est single predictor of response to anti-PD-1 therapy 
[140]. Other investigators have identified CD8 density at 
the leading edge of the tumor as the single factor most 
closely associated with response. The potential predictive 
value of immune factors in pre-treatment tumor samples 
in patients receiving anti-PD-1 may be further enhanced 
by studying multiple measures associated with the adap-
tive immune resistance phenomenon, rather than a single 
factor [141]. Such markers are highly desirable as some 
patients will demonstrate a delayed response or even par-
adoxical tumor growth before regression, and if they can 
be identified as likely clinical responders, treatment can 
be continued with confidence. Further, there are potential 
immune-related side effects with checkpoint blockade 
agents, so biomarkers that can help shift the cost:benefit 
ratio for patients are highly sought after. In the future, 
additional characterization of the pre-treatment and 
on-treatment tumor microenvironment will likely facili-
tate the rational design of combinatorial treatments with 
anti-PD-1/L1 agents and help to further improve patient 
outcomes.
The role of BRAF and NRAS in the immunological 
landscape of melanoma has been poorly investigated and 
the effect of their mutations on global gene expression 
remains to be fully elucidated. Two immune phenotypes 
have been described in melanoma: a Th1 phenotype, 
characterized by the expression of melanocytic line-
age specific transcripts, a better prognosis and higher 
responsiveness to immunotherapy, and a Th17 pheno-
type, associated to enhanced cellular motility, poorer 
prognosis and a more undifferentiated status. A classifi-
cation that differentiate melanoma metastases based on 
genes consistently expressed in vivo and in vitro has been 
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previously identified [142] and named transcriptional 
adjustments related to amplification/deletions (TARA), 
which resembles the pattern created in breast cancer 
with Luminal or Basal-like classification. One-hundred-
thirteen metastatic melanoma tissues have been classi-
fied according to TARA; TARA class A displayed a classic 
Th17 phenotype, with expression of IL-17, IL-1, TNF-
alpha and IL-23, while TARA class B identified a typi-
cal Th1 phenotype with expression of STAT1, GBP1 and 
CXCL10. Authors have also examined patterns of BRAF 
and NRAS mutations in these 113 metastatic tissues: 
29 % were wild-type, 59 % had a BRAF mutation and 12 % 
a NRAS mutation. BRAF and NRAS mutations did not 
affect the transcriptome at global level, however, BRAF-
specific genes discriminated Th1/good vs. Th17/poor 
phenotype. The association between BRAF mutation and 
poor phenotype was particularly strong in samples dis-
playing low BRAF mRNA expression. Functional inter-
pretation of genes differentially expressed in metastases 
displaying high and low BRAF mRNA revealed IL-2 and 
JAK/Stat among the top canonical pathways. This sug-
gests that BRAF mRNA expression may also play a role 
in the association to an immune phenotype in melanoma.
Uveal melanoma is the most common intraocular 
malignancy in the adults, originating from the melano-
cytes located in the human uvea. The most frequent 
site of onset are the ciliary body and choroid (95  % of 
cases), more rarely the iris (5  %) is affected. Uveal mel-
anoma patients have a disease-specific 5-year survival 
around 40  %. Driver mutations in GNAQ and GNA11 
can be found in about 80 % of uveal melanomas, which 
is thereby genetically different from cutaneous and con-
junctival melanoma [143, 144]. While localized disease 
can be treated with surgery or radiotherapy, there is lack 
of effective treatments for metastatic uveal melanoma. A 
meta-analysis of 40 clinical trials (only 1 of them being 
a phase 3 randomized trial) enrolling more than 800 
patients showed a less than 5 % ORR and a median PFS 
of 1.8–7.1  months [145]. Due to the critical role of the 
RAF/MEK/ERK signaling pathway in uveal melanoma, 
clinical trials with specific inhibitors such as sulemetinib, 
sorafenib and MEK162 are ongoing [146]. Uveal mela-
nomas do express some tumor antigens such as GP100, 
MART-1, tyrosinase and TRP-1 [147]. These tumors 
also create an inflammatory microenvironment and 
have a functionally relevant PD-L1 expression, provid-
ing a rationale for immunotherapy. In expanded access 
programs and retrospective studies, ipilimumab showed 
some activity in patients with metastatic uveal melanoma. 
The largest dataset included 82 unselected patients, in 
which disease control rate was 30 % with a median PFS 
of 3.6  months and a 1-year-survival rate of 31  % [148]. 
Recently, a phase II trial by DeCOG (Dermatologic 
Oncology Cooperative Group) which aimed to prospec-
tively evaluate the efficacy and safety of ipilimumab in 
patients with cutaneous melanoma and rare subgroups 
was published [149]. In this trial, 53 patients with uveal 
melanoma were included, with 85  % of cases having at 
least one prior systemic therapy. In these patients, how-
ever, ipilimumab did not show any relevant activity. No 
objective response has been reported, with median PFS 
was 2.83 months and only 22 % of patients alive at 1 year. 
The presence of brain metastases and of a prior treatment 
was not associated with decreased survival. Conversely, 
pretreatment LDH levels (low vs. high) and absolute 
lymphocyte count (high vs. low) were associated with 
improved survival. The reasons why ipilimumab showed 
such limited activity in metastatic uveal melanomas are 
not clear. To further evaluate immune-checkpoint block-
ade in uveal melanoma, a new murine model was estab-
lished using stably transduced melan-a cells expressing 
an activating mutation of the uveal melanoma oncogene 
GNAQ. In this model, dual therapeutic immune check-
point blockade (anti-CTLA-4 and anti-PD-1) is needed 
in order to delay tumor growth, showing no activity if 
either agent was administered as monotherapy (Schil-
ling and Griewank unpublished). To further evaluate the 
role of immune-checkpoint blockade in uveal melanoma, 
additional preclinical studies might provide new insight 
into the interaction of uveal melanoma and the host’s 
immune system. However, only prospective, randomized 
trials will be able evaluate the full potential of immuno-
therapy in metastatic uveal melanoma.
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